Skip to main content
LQDA
NASDAQ Life Sciences

Director-Affiliated Entity Canaan VIII LP Files to Sell Another $13M in Liquidia Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$65.31
Mkt Cap
$5.803B
52W Low
$11.85
52W High
$66.775
52W Position info
451% above low
Off High info
2.2% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $11.85.

Summary

Canaan VIII LP, a director-affiliated entity, has filed a Form 144 to sell an additional $13 million worth of Liquidia Corp common stock, continuing a pattern of significant insider distribution.


Key Events · Ownership and Investor Activity · LQDA

  • Proposed Stock Sale

    Canaan VIII LP intends to sell 200,000 shares of Liquidia Corp common stock, valued at approximately $13 million.

  • Filer Identity

    The selling entity, Canaan VIII LP, is affiliated with a director of Liquidia Corp.

  • Ongoing Distribution Pattern

    This filing extends a recent trend of significant stock sales by Canaan VIII LP, which has sold over $43 million in the past three months through multiple Form 144 filings.

  • Market Context

    The proposed sale occurs while Liquidia's stock is trading near its 52-week high, following recent positive news regarding Q1 earnings and S&P SmallCap 600 Index inclusion.


Analysis · LQDA · Life Sciences

This Form 144 indicates a significant intent to sell by Canaan VIII LP, an institutional investor with director affiliation. The $13 million proposed sale, representing a notable portion of the company's market capitalization, is substantial. This is part of a broader pattern of distribution by Canaan VIII LP, which has filed multiple Form 144s and sold over $43 million in the last three months. While Liquidia recently reported strong Q1 results and upcoming S&P SmallCap 600 inclusion, this continued insider selling by a major institutional holder could exert downward pressure on the stock, especially as it trades near its 52-week high.

At the time of this filing, LQDA was trading at $65.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $11.85 to $66.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Jul 24, 2026, 4:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $86.22
Real-time Price: $86.16 info
Change: -$0.060 (-0.07%) info
Market Cap: $7.667B info
LQDA
Jun 12, 2026, 4:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $71.23
Real-time Price: $86.16 info
Change: +$14.93 (+21%) info
Market Cap: $7.667B info
LQDA
Jun 08, 2026, 4:41 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $64.69
Real-time Price: $86.16 info
Change: +$21.47 (+33%) info
Market Cap: $7.667B info
LQDA
Jun 08, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $64.69
Real-time Price: $86.16 info
Change: +$21.47 (+33%) info
Market Cap: $7.667B info
LQDA
Jun 08, 2026, 4:11 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $63.90
Real-time Price: $86.16 info
Change: +$22.26 (+35%) info
Market Cap: $7.667B info